These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30571121)
21. Functional Characterisation of ClpP Mutations Conferring Resistance to Acyldepsipeptide Antibiotics in Firmicutes. Malik IT; Pereira R; Vielberg MT; Mayer C; Straetener J; Thomy D; Famulla K; Castro H; Sass P; Groll M; Brötz-Oesterhelt H Chembiochem; 2020 Jul; 21(14):1997-2012. PubMed ID: 32181548 [TBL] [Abstract][Full Text] [Related]
22. Bacterial caseinolytic proteases as novel targets for antibacterial treatment. Brötz-Oesterhelt H; Sass P Int J Med Microbiol; 2014 Jan; 304(1):23-30. PubMed ID: 24119566 [TBL] [Abstract][Full Text] [Related]
23. Ureadepsipeptides as ClpP Activators. Griffith EC; Zhao Y; Singh AP; Conlon BP; Tangallapally R; Shadrick WR; Liu J; Wallace MJ; Yang L; Elmore JM; Li Y; Zheng Z; Miller DJ; Cheramie MN; Lee RB; LaFleur MD; Lewis K; Lee RE ACS Infect Dis; 2019 Nov; 5(11):1915-1925. PubMed ID: 31588734 [TBL] [Abstract][Full Text] [Related]
24. ClpP inhibitors are produced by a widespread family of bacterial gene clusters. Culp EJ; Sychantha D; Hobson C; Pawlowski AC; Prehna G; Wright GD Nat Microbiol; 2022 Mar; 7(3):451-462. PubMed ID: 35246663 [TBL] [Abstract][Full Text] [Related]
25. A simple fragment of cyclic acyldepsipeptides is necessary and sufficient for ClpP activation and antibacterial activity. Carney DW; Compton CL; Schmitz KR; Stevens JP; Sauer RT; Sello JK Chembiochem; 2014 Oct; 15(15):2216-20. PubMed ID: 25212124 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and antibacterial activity studies of thiazole derivatives as potent ecKAS III inhibitors. Cheng K; Xue JY; Zhu HL Bioorg Med Chem Lett; 2013 Jul; 23(14):4235-8. PubMed ID: 23731945 [TBL] [Abstract][Full Text] [Related]
27. The Role of ClpP Protease in Bacterial Pathogenesis and Human Diseases. Bhandari V; Wong KS; Zhou JL; Mabanglo MF; Batey RA; Houry WA ACS Chem Biol; 2018 Jun; 13(6):1413-1425. PubMed ID: 29775273 [TBL] [Abstract][Full Text] [Related]
28. Application of fragment-based screening to the design of inhibitors of Escherichia coli DsbA. Adams LA; Sharma P; Mohanty B; Ilyichova OV; Mulcair MD; Williams ML; Gleeson EC; Totsika M; Doak BC; Caria S; Rimmer K; Horne J; Shouldice SR; Vazirani M; Headey SJ; Plumb BR; Martin JL; Heras B; Simpson JS; Scanlon MJ Angew Chem Int Ed Engl; 2015 Feb; 54(7):2179-84. PubMed ID: 25556635 [TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of thiazole derivatives as potent FabH inhibitors with antibacterial activity. Li JR; Li DD; Wang RR; Sun J; Dong JJ; Du QR; Fang F; Zhang WM; Zhu HL Eur J Med Chem; 2014 Mar; 75():438-47. PubMed ID: 24561667 [TBL] [Abstract][Full Text] [Related]
30. Structure of Staphylococcus aureus ClpP Bound to the Covalent Active-Site Inhibitor Cystargolide A. Illigmann A; Vielberg MT; Lakemeyer M; Wolf F; Dema T; Stange P; Kuttenlochner W; Liebhart E; Kulik A; Staudt ND; Malik I; Grond S; Sieber SA; Kaysser L; Groll M; Brötz-Oesterhelt H Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202314028. PubMed ID: 38029352 [TBL] [Abstract][Full Text] [Related]
31. Disruption of oligomerization and dehydroalanine formation as mechanisms for ClpP protease inhibition. Gersch M; Kolb R; Alte F; Groll M; Sieber SA J Am Chem Soc; 2014 Jan; 136(4):1360-6. PubMed ID: 24106749 [TBL] [Abstract][Full Text] [Related]
32. Proteolysis of the proofreading subunit controls the assembly of Escherichia coli DNA polymerase III catalytic core. Bressanin D; Stefan A; Piaz FD; Cianchetta S; Reggiani L; Hochkoeppler A Biochim Biophys Acta; 2009 Nov; 1794(11):1606-15. PubMed ID: 19635595 [TBL] [Abstract][Full Text] [Related]
33. Comparative genomics and functional roles of the ATP-dependent proteases Lon and Clp during cytosolic protein degradation. Chandu D; Nandi D Res Microbiol; 2004 Nov; 155(9):710-9. PubMed ID: 15501647 [TBL] [Abstract][Full Text] [Related]
34. Barrel-shaped ClpP Proteases Display Attenuated Cleavage Specificities. Gersch M; Stahl M; Poreba M; Dahmen M; Dziedzic A; Drag M; Sieber SA ACS Chem Biol; 2016 Feb; 11(2):389-99. PubMed ID: 26606371 [TBL] [Abstract][Full Text] [Related]
35. Molecular determinants of complex formation between Clp/Hsp100 ATPases and the ClpP peptidase. Kim YI; Levchenko I; Fraczkowska K; Woodruff RV; Sauer RT; Baker TA Nat Struct Biol; 2001 Mar; 8(3):230-3. PubMed ID: 11224567 [TBL] [Abstract][Full Text] [Related]
36. Molecular properties of ClpAP protease of Escherichia coli: ATP-dependent association of ClpA and clpP. Maurizi MR; Singh SK; Thompson MW; Kessel M; Ginsburg A Biochemistry; 1998 May; 37(21):7778-86. PubMed ID: 9601038 [TBL] [Abstract][Full Text] [Related]
37. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. Lee BG; Park EY; Lee KE; Jeon H; Sung KH; Paulsen H; Rübsamen-Schaeff H; Brötz-Oesterhelt H; Song HK Nat Struct Mol Biol; 2010 Apr; 17(4):471-8. PubMed ID: 20305655 [TBL] [Abstract][Full Text] [Related]
39. Reversible Inhibitors Arrest ClpP in a Defined Conformational State that Can Be Revoked by ClpX Association. Pahl A; Lakemeyer M; Vielberg MT; Hackl MW; Vomacka J; Korotkov VS; Stein ML; Fetzer C; Lorenz-Baath K; Richter K; Waldmann H; Groll M; Sieber SA Angew Chem Int Ed Engl; 2015 Dec; 54(52):15892-6. PubMed ID: 26566002 [TBL] [Abstract][Full Text] [Related]
40. Molecular symmetry of the ClpP component of the ATP-dependent Clp protease, an Escherichia coli homolog of 20 S proteasome. Shin DH; Lee CS; Chung CH; Suh SW J Mol Biol; 1996 Sep; 262(2):71-6. PubMed ID: 8831780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]